絞り込み

16645

広告

氷上のワカサギ釣り解禁 暖冬で10日遅れ 前橋 群馬

前橋市の、赤城山にある湖で冬の風物詩、氷上のワカサギ釣りが暖冬による影響で例年よりも10日ほど遅れて22日朝、解禁され多くの愛好家でにぎわっています。

  1. 新型ウイルス肺炎 死者9人 患者440人...
  2. 色々な色の名前、日本語と英語での名前、伝...
  3. 調達情報 企業啓発用ガイドブック201,...
  4. 調達情報 令和2年度~令和4年度診療報酬...

ニュース一覧

Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low-dose afatinib: A case report.

著者 Iida Y , Kumasawa F , Shimizu T , Shintani Y , Takahashi N , Gon Y
Thorac Cancer.2019 Nov 28 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (18view , 0users)

Full Text Sources

Miscellaneous

There are limited data on the clinical efficiency of afatinib in non-small cell lung cancer (NSCLC) patients with uncommon epidermal growth factor receptor (EGFR) mutations. Moreover, the efficacy and safety of afatinib in elderly patients with these mutations has not been established. Here, we describe a case of successful treatment of a patient aged >80 years with lung adenocarcinoma positive for the uncommon EGFR L861Q mutation with low-dose afatinib. An 83-year-old woman presented with cough and dyspnea. A chest computed tomography (CT) scan revealed tumors in the left upper lobe, left pleural effusion, and multiple lung metastases in both lungs. The patient was diagnosed with lung adenocarcinoma with an EGFR L861Q mutation based on cytological findings. The patient received 30 mg/day of afatinib and experienced no severe adverse events. Two weeks later, partial response was observed based on a CT scan. The results of the present case support the effectiveness and safety of low-dose afatinib in elderly patients with EGFR L861Q mutation-positive NSCLC.
PMID: 31779047 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード